FIA
CASI

FNY Investment Advisers’s CASI Pharmaceuticals CASI Stock Holding History

FNY Investment Advisers’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,940
Closed -$118K – 791
2021
Q1 		$118K Buy
+4,940
New +$139K 0.04% 284

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Investment Advisers's CASI Position: Q2 2021 in Review

FNY Investment Advisers sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 4,940 shares — an estimated $118K sold.

FNY Investment Advisers first reported a position in CASI in Q1 2021 and held it in 1 quarter. The position peaked at $118K in Q1 2021. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • FNY Investment Advisers reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 4,940 CASI Pharmaceuticals shares in Q2 2021, an estimated $118K.
  • FNY Investment Advisers first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • FNY Investment Advisers's CASI Pharmaceuticals position peaked at $118K in Q1 2021.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on FNY Investment Advisers's 13F filing for Q2 2021, filed 14 Jul 2021.